New Framework Clarifies Cold Start Evaluation for Drug Interaction Prediction Models

In a Perspective authored by Xiaoqing Ru, Yansu Wang, Quan Zou, and Mengting Niu, researchers argue that cold-start evaluation for drug–drug interaction and drug–target interaction models must be treated as an auditable deployment claim. Reliable generalization is critical before deploying these computational models in drug discovery, pharmacovigilance, and clinical decision support. However, the authors observe that strong performance reported on random splits or weakly constrained evaluations may fail to demonstrate how effectively a model generalizes when confronted with new drugs, novel targets, or unfamiliar deployment conditions.

A primary challenge identified in pairwise prediction is that test instances may closely resemble training examples in molecular structure, biological sequence, or network context. Such persistent overlap can artificially inflate performance estimates, leading researchers to mistake simple data interpolation for true model extrapolation.

To establish rigorous benchmarks, the authors systematically categorize common evaluation settings by their underlying source and scope of novelty, organizing them into an L0 through L5 framework. This structured hierarchy encompasses random splits and entity-disjoint protocols, as well as structure-level, temporal, domain-disjoint, and many-domain evaluations. By explicitly defining this range, the L0 through L5 framework clarifies the precise deployment claim that each evaluation setting is designed to test, preventing mismatched validation assumptions.

To measure the gap between training and testing data, the authors identify coverage, overlap, and distance as key quantitative measures of train–test discrepancy. In addition, the Perspective provides an operational checklist addressing leakage control, validation alignment, candidate-pair construction, and domain-level risk reporting. Together, these contributions clarify the boundaries and evidential scope of cold-start evaluation, establishing a common foundation for accurately interpreting and comparing model performance across drug–drug and drug–target interaction studies.

Subject of Research: Cold-start evaluation framework for drug interaction prediction models

Article Title: Beyond unseen entities: Auditable cold-start evaluation for drug interaction prediction

Article References: Ru, X., Wang, Y., Zou, Q., & Niu, M. (2026). Beyond unseen entities: Auditable cold-start evaluation for drug interaction prediction. PLOS Computational Biology, 22(11), e1014927. https://doi.org/10.1371/journal.pcbi.1014927

Image Credits: AI Generated

DOI: 10.1371/journal.pcbi.1014927

Keywords: drug–drug interaction, drug–target interaction, cold-start evaluation, auditable deployment claims, pairwise prediction, generalization, random splits, entity-disjoint protocols, structure-level evaluation, temporal evaluation, domain-disjoint evaluation, many-domain evaluation, L0–L5 framework, train–test discrepancy, leakage control, validation alignment, candidate-pair construction, domain-level risk reporting